secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001104659-25-009387
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio enters first patients into pivotal Phase 3 Alzheimer's study of buntanetap
--------------------------------------------------------------------------------

- First two patients enrolled in pivotal Phase 3 trial of buntanetap for early Alzheimer's disease.
- Trial is 18-month, randomized, placebo-controlled, double-blind with primary endpoints ADAS-Cog13 and ADCS-iADL.
- Over 750 participants expected across ~100 US sites; FDA-approved protocol.
- Company raised $21M gross from public offering of 5.25M units to fund initial 6 months; 12-month from warrant exercises.
- CEO cites prior Phase 2/3 data showing cognitive improvement and no safety concerns.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925009387/0001104659-25-009387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925009387/tm255497d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-009387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer